Read by QxMD icon Read

radiotherapy for carcinoma prostate

John Heesakkers, Fawzy Farag, Ricarda M Bauer, Jaspreet Sandhu, Dirk De Ridder, Arnulf Stenzl
CONTEXT: The incidence and awareness of postprostatectomy incontinence (PPI) has increased during the past few years, probably because of an increase in prostate cancer surgery. Many theories have been postulated to explain the pathophysiology of PPI. OBJECTIVE: The current review scrutinizes various pathophysiologic mechanisms underlying the occurrence of PPI. EVIDENCE ACQUISITION: A search was conducted on PubMed and EMBASE for publications on PPI...
October 6, 2016: European Urology
Georgios Gakis, Peter C Black, Bernard H Bochner, Stephen A Boorjian, Arnulf Stenzl, George N Thalmann, Wassim Kassouf
CONTEXT: Urothelial carcinoma is considered a pan-urothelial disease. As such, the remnant urothelium in the upper urinary tract and urethra following radical cystectomy (RC) remains at risk for secondary urothelial tumors (SUTs). OBJECTIVE: To describe the incidence, diagnosis, treatment, and outcomes of patients with SUTs after RC. EVIDENCE ACQUISITION: A systematic search was conducted using PubMed database according to Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines to identify studies between 1970 and 2016 reporting on malignant diseases of the urothelium after RC for bladder cancer...
October 6, 2016: European Urology
Zachary A Glaser, Matthew White, Elizabeth McKinley, Jeffrey S Glaser
No abstract text is available yet for this article.
August 20, 2016: Clinical Genitourinary Cancer
Clemens Kratochwil, Ali Afshar-Oromieh, Klaus Kopka, Uwe Haberkorn, Frederik L Giesel
The prostate-specific membrane antigen (PSMA) is expressed by approximately 90% of prostate carcinomas. The expression correlates with unfavorable prognostic factors, such as a high Gleason score, infiltrative growth, metastasis, and hormone-independence. The high specificity, especially in the undifferentiated stage, makes it an excellent target for diagnosis and therapy. Therefore, antibodies and small molecule inhibitors have been developed for imaging and therapy. In 2011 PSMA-11, a ligand that consists of the Glu-urea-motif and the chelator HBED-CC, which can be exclusively radiolabeled with (68)Ga for PET imaging, presented the clinical breakthrough for prostate cancer diagnostics...
September 2016: Seminars in Nuclear Medicine
Charlotte F Kweldam, Intan P Kümmerlin, Daan Nieboer, Esther I Verhoef, Ewout W Steyerberg, Luca Incrocci, Chris H Bangma, Theodorus H van der Kwast, Monique J Roobol, Geert J van Leenders
AIM OF THE STUDY: Gleason score (GS) 3 + 4 = 7 prostate cancer patients with presence of cribriform or intraductal carcinoma (7(+)) have a worse disease-specific survival than those without. The aim of this study was to compare the clinicopathologic characteristics and patient outcomes of men with biopsy GS 3 + 4 = 7 without cribriform or intraductal carcinoma (7(-)) to those with GS 3 + 3 = 6. MATERIALS AND METHODS: We included all patients from the first screening round of the European Randomized Study of Screening for Prostate Cancer (1993-2000) with a revised GS ≤ 3 + 4 = 7 (n = 796) following the 2014 International Society of Urological Pathology criteria...
October 2016: European Journal of Cancer
Arvind Kumar Shukla, Sanjeev Kumar, I S Sandhu, Arun S Oinam, Ranjit Singh, Rakesh Kapoor
PURPOSE: The quality of intensity-modulated radiotherapy (IMRT) highly depends on the choice of beam orientations and optimization algorithms used in the treatment planning. The present work reports dosimetric study of IMRT plans generated using preselected equiangular beam orientations (PSBO) and beam angle optimization (BAO) for the patients of prostate, head and neck, and esophagus carcinoma. MATERIALS AND METHODS: The computed tomography (CT) datasets of 30 patients treated with IMRT for prostate, head and neck, and esophagus carcinoma were selected...
April 2016: Journal of Cancer Research and Therapeutics
Hun Jung Kim, Jeong Hoon Phak, Woo Chul Kim
Purpose: Stereotactic body radiotherapy (SBRT) takes advantage of low α/β ratio of prostate cancer to deliver a large dose in few fractions. We examined clinical outcomes of SBRT using CyberKnife for the treatment of low- and intermediate-risk prostate cancer. Materials and Methods: This study was based on a retrospective analysis of the 33 patients treated with SBRT using CyberKnife for localized prostate cancer (27.3% in low-risk and 72.7% in intermediate-risk)...
June 17, 2016: Radiation Oncology Journal
Amir Iravani Tabrizipour, Lily Shen, Robert Mansberg, Bui Chuong
Extrapulmonary primary small cell carcinomas arising from the urogenital tract is infrequent. It can rarely arise from the prostate and even more rarely from the seminal vesicles. We present a 79-year-old male who was admitted due to acute renal failure with a history of radical radiotherapy for prostate adenocarcinoma 13 years ago. The prostate specific antigen level was not elevated. An abdominopelvic computed tomography (CT) scan showed markedly enlarged seminal vesicles causing bilateral ureteral obstruction and a mildly enlarged prostate...
February 5, 2016: Molecular Imaging and Radionuclide Therapy
Fergus Keane, Aoife M Egan, Patrick Navin, Francesca Brett, Michael C Dennedy
UNLABELLED: Pituitary apoplexy represents an uncommon endocrine emergency with potentially life-threatening consequences. Drug-induced pituitary apoplexy is a rare but important consideration when evaluating patients with this presentation. We describe an unusual case of a patient with a known pituitary macroadenoma presenting with acute-onset third nerve palsy and headache secondary to tumour enlargement and apoplexy. This followed gonadotropin-releasing hormone (GNRH) agonist therapy used to treat metastatic prostate carcinoma...
2016: Endocrinology, Diabetes & Metabolism Case Reports
Zhen Cai, Chao Zhu, Lizhen Wang, Ling Zhu, Zhiyuan Zhang, Hanguang Zhu, Yan'an Wang
Mandibular metastatic carcinoma is a rare lesion that accounts for <1% of all oral malignancies. To provide greater experience in this field, the present study was conducted in which 6 cases of mandibular metastatic carcinoma were retrospectively reviewed. The origin of the lesions was the prostate in 2 cases, the lungs in 2 cases, the breast in 1 case and the thyroid gland in 1 case. The clinical and computed tomography features, surgical management and follow-up outcomes were investigated. The study indicated that surgeons should include the suspicion of metastasis in the differential diagnosis for mandibular tumor, particularly in patients who have a history of malignancy...
June 2016: Oncology Letters
Roger Shen, Jane J Kim, Mingyi Yao, Tamer A Elbayoumi
Berberine (Brb) is an active alkaloid occurring in various common plant species, with well-recognized potential for cancer therapy. Brb not only augments the efficacy of antineoplastic chemotherapy and radiotherapy but also exhibits direct antimitotic and proapoptotic actions, along with distinct antiangiogenic and antimetastatic activities in a variety of tumors. Despite its low systemic toxicity, several pharmaceutical challenges limit the application of Brb in cancer therapy (ie, extremely low solubility and permeability, very poor pharmacokinetics (PKs), and oral bioavailability)...
2016: International Journal of Nanomedicine
Hana Jedlickova, Veronika Durčanská, Vladimír Vašků
Dear Editor, Scleroderma associated with neoplasia is rare, with only a small number of cases reported. We describe 4 patients with paraneoplastic scleroderma who were treated at the I. Department of Dermatovenereology, St. Anna Hospital, during the period between 2004 and 2014. The patients were diagnosed with cholangiogenic carcinoma, endometrial carcinoma, prostatic adenocarcinoma, and adenoma of the suprarenal gland. In the case of concurrent scleroderma and tumor, four situations may occur: they can develop independently of each other; scleroderma may be induced by the tumor; the tumor can develop in the scleroderma; or the tumor can be induced by immunosuppressive therapy...
April 2016: Acta Dermatovenerologica Croatica: ADC
Susanne Lütje, Wolfgang Sauerwein, Thomas Lauenstein, Andreas Bockisch, Thorsten D Poeppel
As the prostate-specific membrane antigen (PSMA) is overexpressed in the neovasculature of several malignancies, it might serve as a target in oncology. Ga-PSMA PET/CT and PET/MRI were performed in a female who developed pulmonary metastases from an adenoid cystic carcinoma of the right sublingual salivary gland after incomplete resection of the primary tumor and radiotherapy. Uptake of Ga-PSMA in tumors was observed, indicating PSMA expression. Moreover, a new cerebral metastasis was detected. Potentially, Ga-PSMA PET might be used for noninvasive assessment of adenoid cystic carcinoma to evaluate whether patients apply for PSMA-based radiotherapy when no further treatment options are available...
June 2016: Clinical Nuclear Medicine
Cheng Pang, Youyan Guan, Hongbo Li, Wanqing Chen, Gang Zhu
Cancer remains to be the second most common cause of death, and its incidence and mortality rates are increasing in China. According to the 2015 National Central Cancer Registry (NCCR) of China, the incidence of bladder cancer and prostate cancer ranked sixth and seventh, respectively, in male cancers. The majority of prostate cancer patients were diagnosed at an advanced stage. Early diagnosis of prostate cancer is the key to improve prostate cancer survival in China. Radical prostatectomy or radical radiotherapy is the main treatment for localized prostate cancer, and a comprehensive therapy based on androgen deprivation therapy is the treatment for advanced disease...
June 2016: Japanese Journal of Clinical Oncology
Eric K Yeoh, Robin Krol, Varinderpal S Dhillon, Rochelle Botten, Addolorata Di Matteo, Julie Butters, Aleisha R Brock, Adrian Esterman, Carolyn Salisbury, Michael Fenech
Background Chronic gastrointestinal (GI) morbidity occurs in ≥50% of patients after external beam radiotherapy (EBRT) for carcinoma of prostate (CaP). This prospective, longitudinal study examines which baseline measurements of: 1) homocysteine and micronutrients in plasma; 2) chromosome damage/misrepair biomarkers; and 3) anal and rectal dose volume metrics predict GI morbidity after EBRT. Patients and methods In total, 106 patients with CaP had evaluations of GI symptoms (modified LENT-SOMA questionnaires) before EBRT and at one month, one, two and three years after its completion...
May 2016: Acta Oncologica
Michel Bolla, Philippe Maingon, Christian Carrie, Salvador Villa, Petros Kitsios, Philip M P Poortmans, Santhanam Sundar, Elzbieta M van der Steen-Banasik, John Armstrong, Jean-François Bosset, Fernanda G Herrera, Bradley Pieters, Annerie Slot, Amit Bahl, Rahamim Ben-Yosef, Dirk Boehmer, Christopher Scrase, Laurette Renard, Emad Shash, Corneel Coens, Alphonsus C M van den Bergh, Laurence Collette
PURPOSE: Up to 30% of patients who undergo radiation for intermediate- or high-risk localized prostate cancer relapse biochemically within 5 years. We assessed if biochemical disease-free survival (DFS) is improved by adding 6 months of androgen suppression (AS; two injections of every-3-months depot of luteinizing hormone-releasing hormone agonist) to primary radiotherapy (RT) for intermediate- or high-risk localized prostate cancer. PATIENTS AND METHODS: A total of 819 patients staged: (1) cT1b-c, with prostate-specific antigen (PSA) ≥ 10 ng/mL or Gleason ≥ 7, or (2) cT2a (International Union Against Cancer TNM 1997), with no involvement of pelvic lymph nodes and no clinical evidence of metastatic spread, with PSA ≤ 50 ng/mL, were centrally randomized 1:1 to either RT or RT plus AS started on day 1 of RT...
May 20, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Raquel F D van la Parra, Henry M Kuerer
With improvements in chemotherapy regimens, targeted therapies, and our fundamental understanding of the relationship of tumor subtype and pathologic complete response (pCR), there has been dramatic improvement in pCR rates in the past decade, especially among triple-negative and human epidermal growth factor receptor 2-positive breast cancers. Rates of pCR in these groups of patients can be in the 60 % range and thus question the paradigm for the necessity of breast and nodal surgery in all cases, particularly when the patient will be receiving adjuvant local therapy with radiotherapy...
2016: Breast Cancer Research: BCR
Jekwon Yeh, Brandon Lehrich, Carolyn Tran, Albert Mesa, Ruben Baghdassarian, Jeffrey Yoshida, Robert Torrey, Michael Gazzaniga, Alan Weinberg, Stuart Chalfin, John Ravera, Kenneth Tokita
PURPOSE: To present rectal toxicity rates in patients administered a polyethylene glycol (PEG) hydrogel rectal spacer in conjunction with combination high-dose-rate brachytherapy and external beam radiotherapy. METHODS AND MATERIALS: Between February 2010 and April 2015, 326 prostate carcinoma patients underwent combination high-dose-rate brachytherapy of 16 Gy (average dose 15.5 Gy; standard deviation [SD] = 1.6 Gy) and external beam radiotherapy of 59.4 Gy (average dose 60...
May 2016: Brachytherapy
Aurélien Wahart, Jean-Baptiste Guy, Alexis Vallard, Benjamin Geissler, Majed Ben Mrad, Alexander T Falk, Nathalie Prevot, Guy de Laroche, Chloé Rancoule, Cyrus Chargari, Nicolas Magné
OBJECTIVE: The aim of this study was to report the first cases of salvage radiotherapy (RT) using the intensity-modulated radiotherapy (IMRT) with simultaneous integrated boost (SIB) targeted on choline positron emission tomography (PET) uptake in a local recurrent prostate cancer, after a radical prostatectomy. METHODS: Four patients received salvage irradiation for biochemical relapse that occurred after the initial radical prostatectomy. The relapse occurred from 10 months to 6 years with PSA levels ranging from 2...
2016: British Journal of Radiology
Anthony Kodzo-Grey Venyo
Primary leiomyosarcoma of the prostate (PLSOP) is rare, with less than 200 cases reported so far. PLSOPs present with lower urinary tract symptoms, haematuria, and perineal pain; may or may not be associated with a history of previous treatment for adenocarcinoma of prostate by means of radiotherapy and or hormonal treatment; may afflict children and adult male. Examination may reveal benign enlarged prostate and hard enlarged mass. PLSOPs may be diagnosed by histological examination findings of spindle-shaped carcinoma cells in prostate specimens...
2015: Advances in Urology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"